Real-World Early Treatment with Room Temperature–Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses

Treating hemophilia A or B patients with inhibitors is particularly challenging, as they do not respond to replacement therapy with factor VIII or factor IX concentrates. A room temperature–stable formulation of recombinant activated factor VII (rFVIIa; NovoSeven®), which provides improved convenien...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Francesco Demartis, Angelika Batorova, Hervé Chambost, Peyman Eshghi, Mehran Karimi, Kaan Kavakli, Soraya Benchikh El Fegoun, Katarina Cepo, Lene Sommer Vestergaard, Gary Benson
Formato: Artigo
Idioma:Inglês
Publicado: Georg Thieme Verlag KG 2017-07-01
Series:TH Open
Assuntos:
bleeding
efficacy
eptacog alfa activated
novoseven®
rfviia
Acceso en liña:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0037-1608943
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares